Market Overview

UPDATE: Taglich Brothers Raises PT to $13.25 on Novadaq Technologies on Valuation

Morning Market Movers
Profound Medical Appoints Dr. Arun Menawat To Board Of Directors

Taglich Brothers reiterated its Buy rating on Novadaq Technologies (NASDAQ: NVDQ) and increased its price target from $11 to $13.25.

Taglich Brothers commented, "Reconstructive, cardiac and urological surgery markets have been penetrated to an extent that has made Novadaq cash flow positive. Novadaq aims to commercialize, on its own, the PINPOINT endoscopic imaging systems for minimally invasive surgeries. Substantial development costs for PINPOINT will continue to burn cash through next year. But fortified with $37 million in proceeds from a common stock offering, Novadaq is well prepared for expanded product development and penetration of additional large markets."

Taglich Brothers closed at $9.11 on Wednesday.

Latest Ratings for NVDQ

Jan 2015JMP SecuritiesMaintainsMarket Outperform
Nov 2014Taglich BrothersMaintainsBuy
Aug 2014Canaccord GenuityMaintainsBuy

View More Analyst Ratings for NVDQ
View the Latest Analyst Ratings

Posted-In: taglich brothersAnalyst Color Price Target Pre-Market Outlook Analyst Ratings


Related Articles (NVDQ)

Around the Web, We're Loving...